Opioid detox for Hollywood — fentanyl-era protocols, buprenorphine done right.

RECO Island runs small-census, physician-led opioid detox 35 miles north of Hollywood — 50 minutes up I-95 from Hollywood Beach, Emerald Hills, and Oakwood. The buprenorphine and naltrexone protocols reflect current fentanyl-era addiction medicine: COWS-guided induction, micro-induction when clinically indicated, and comfort medication written for medical comfort rather than stoic endurance. The detox bed and the residential bed are on the same campus, so step-down from acute withdrawal to residential treatment happens in-house with no waitlist and no third-party handoff.

The drive from Hollywood to RECO Island’s Delray Beach campus is 35 miles up I-95 — roughly 50 minutes outside rush hour. For many residents of Hollywood Beach, Emerald Hills, Hollywood Lakes, Hollywood Hills, and Oakwood entering opioid detox, that distance functions as therapeutic separation from the neighborhoods, contacts, and daily routines tied to active use. The medical detox bed and the residential bed sit on the same campus, so the transition from acute withdrawal to the next phase of treatment does not depend on outside referral, transportation, or waitlist availability.

Opioid withdrawal in the fentanyl era

Fentanyl and its analogs have materially changed the clinical picture of opioid withdrawal. The high potency, extensive lipophilic tissue distribution, and unpredictable pharmacokinetics of illicit fentanyl produce a withdrawal syndrome that emerges faster, hits harder, and follows a less predictable trajectory than heroin or prescription opioid withdrawal. Piloerection, lacrimation, rhinorrhea, myalgia, GI cramping, and autonomic instability arrive on a compressed timeline that can overshoot the moderate withdrawal window before conventional buprenorphine induction can be safely initiated.

The clinical consequence is protocol-level. Buprenorphine induction historically started at 12-24 hours of moderate withdrawal now often requires longer intervals or micro-induction protocols to avoid precipitated withdrawal in fentanyl-exposed patients. Precipitated withdrawal — where a partial agonist displaces a full agonist at the mu receptor and provokes acute worsening — is one of the most preventable adverse events in modern detox medicine, and preventing it requires a protocol built around current addiction medicine practice rather than the pre-fentanyl playbook. RECO Island’s opioid detox program is designed around that reality.

Adulterants complicate the picture. Xylazine, benzodiazepines, and undisclosed stimulants routinely appear in the illicit opioid supply, producing compound withdrawal syndromes that require active surveillance and separate management pathways. Nursing is trained to distinguish opioid withdrawal from concurrent xylazine or benzodiazepine withdrawal, each of which has a distinct clinical course and its own risk profile.

COWS-guided buprenorphine induction

The Clinical Opiate Withdrawal Scale (COWS) scores eleven symptom domains: pulse rate, sweating, restlessness, pupil size, bone and joint aches, rhinorrhea and lacrimation, GI upset, tremor, yawning, anxiety or irritability, and gooseflesh skin. Nursing performs COWS assessments at defined intervals during the induction window, and the numeric score — not the clock — determines induction timing. Buprenorphine induction typically begins when COWS crosses the moderate withdrawal threshold of 11 or higher.

Starting doses are 2-4 mg sublingual, titrated over the first 24 hours to a clinically effective dose (usually 8-16 mg daily, occasionally higher for fentanyl-exposed patients with elevated receptor occupancy). For clients whose COWS trajectory or fentanyl exposure history flags risk of precipitated withdrawal, low-dose or micro-induction protocols are used — small doses of buprenorphine layered alongside continued short-acting opioid exposure until full agonist coverage can be transitioned off safely.

Comfort medications supplement the induction rather than replace it. Clonidine addresses the autonomic storm — hypertension, tachycardia, diaphoresis. Loperamide manages GI hypermotility. Ondansetron controls nausea. Non-opioid analgesics and muscle relaxants address myalgia and restlessness. Trazodone or hydroxyzine supports sleep during the first several nights, when insomnia is near-universal. The clinical goal is a medically comfortable withdrawal that leaves the client able to engage clinically once the acute phase resolves.

Buprenorphine, methadone, or naltrexone — the MAT decision

Post-detox medication for opioid use disorder has three FDA-approved options, each supported by strong evidence for reducing return-to-use and overdose mortality. Buprenorphine is a partial mu agonist with a ceiling effect on respiratory depression, a low overdose profile, and office-based prescribing — the most flexible option and the most common choice at discharge. Methadone is a full agonist dispensed exclusively through federally regulated opioid treatment programs and remains the strongest option for high-dose fentanyl users or clients who have not stabilized on buprenorphine.

Extended-release naltrexone (Vivitrol) is a monthly intramuscular injection of an opioid antagonist. It carries no misuse potential and no respiratory depression risk, but requires a 7-10 day opioid-free window before initiation to avoid precipitated withdrawal — meaning induction happens toward the end of the medical detox stay, not at intake. Naltrexone is often the appropriate choice for clients with occupational licensure considerations, court involvement, prior failure on agonist maintenance, or a stated preference for a non-agonist option.

The MAT decision is made with the client during the detox stay based on clinical picture, prior treatment response, co-occurring diagnoses, and treatment access available at discharge. Case conference includes the attending physician, primary therapist, and the client — it is not templated.

Naloxone education and the safety net

Every RECO Island opioid detox client and their identified support person receives naloxone education and a discharge prescription. The rationale is data-driven: opioid overdose mortality is at its highest in the two weeks immediately following detox. Tolerance has dropped substantially while the risk of return-to-use — even a single use event — remains real, and a dose that was tolerable pre-detox can be fatal post-detox.

Naloxone kits, harm reduction counseling, MAT continuation, and a documented aftercare plan are the evidence-based interventions that reduce that mortality window. Family members are trained to recognize opioid overdose — unresponsiveness, pinpoint pupils, agonal respirations — and to administer intranasal naloxone. This is not optional programming; it is part of the medical standard of care under current addiction medicine guidance from ASAM and SAMHSA.

Clients are also connected with a prescribing clinician at discharge — either through RECO’s continuing care structure or through a warm handoff to a community provider — so that buprenorphine or naltrexone continuity is not interrupted at the moment of highest overdose risk.

What to expect on admission from Hollywood

Admission begins with a phone screen. A clinician takes a substance-use history, verifies benefits, reviews recent use (last use time, quantity, and route matter materially for induction timing), and coordinates transportation from Hollywood — typically same-day or next-morning. Clients driving north on I-95 arrive at the Delray Beach campus for intake; those without transportation can be picked up.

Intake includes medical history, physical exam, urine toxicology, comprehensive metabolic and hematologic labs, and ECG when clinically indicated. A psychiatric evaluation screens for co-occurring conditions using the PHQ-9 for depression, GAD-7 for anxiety, PCL-5 for trauma, and ASRS for adult ADHD. ASAM Criteria dimensions guide the level of care decision and the anticipated transition into residential treatment on the same campus.

Insurance and admissions from Hollywood

RECO Island is in-network with Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS plans commonly held by Hollywood residents through employer coverage or the ACA marketplace. Medical detox for opioid use disorder is covered under the mental health and substance use disorder parity provisions of the ACA. Admissions verifies benefits during the intake call and provides a written out-of-pocket estimate — deductible, coinsurance, and any prior authorization requirements — before arrival. There are no waitlists and no third-party handoffs; the detox bed and the residential bed sit on the same campus, so continuity from acute withdrawal into the next phase of care is not contingent on outside referral.

Serving residents of: Hollywood Beach, Emerald Hills, Hollywood Lakes, Hollywood Hills, Oakwood.